First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic (PD) study.

To enroll or if you have questions about participation

John Sarantopoulos
sarantopoulo@uthscsa.edu
(210) 450-5946

Principal Investigator

John Sarantopoulos

Type of Cancer Treated